Emergent Biosolutions (EBS) reported $743M in revenue for fiscal 2025, −28.8% year on year. That ranks #1966 by revenue among 2853 SEC filers and #186 in Healthcare. Net income was $52.6M, a net margin of 7.1%. Revenue has grown 7.4% a year on average since 2011 ($273M then). The fiscal 2025 balance sheet shows $1.3B in total assets, $205M in cash and $572M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $743M | −28.8% | FY20252025-12-31 |
| Gross profitGrossProfit | $318M | −17.1% | FY20232023-12-31 |
| Operating incomeOperatingIncomeLoss | $100M | +$209M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $52.6M | +$243M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $171M | +190.6% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $13.8M | −39.7% | FY20252025-12-31 |
| Total assetsAssets | $1.3B | −5.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $523M | +8.2% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $205M | +106.4% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $572M | −13.8% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $156M | $6.8M | Open → |
| Q2 20262026-06-30 | $234M | −$180M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Emergent Biosolutions Inc.
- Ticker
- EBS
- Exchange
- NYSE
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001367644
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 1, 2026Open filing →
- 10-KFeb 27, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Alphatec HoldingsATEC | $764M | −$143M |
| Corcept TherapeuticsCORT | $761M | $99.7M |
| Irhythm HoldingsIRTC | $747M | −$45.0M |
| Emergent BiosolutionsEBS | $743M | $52.6M |
| RepligenRGEN | $738M | $48.9M |
| Pacira BiosciencesPCRX | $726M | $7.0M |
| Amphastar PharmaceuticalsAMPH | $720M | $98.1M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Emergent Biosolutions — Key figures |url=https://companiesranked.com/en/company/emergent-biosolutions |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Emergent Biosolutions — Key figures. CompaniesRanked. https://companiesranked.com/en/company/emergent-biosolutionsBibTeX
@misc{companiesranked-en-company-emergent-biosolutions-2026,
author = {{CompaniesRanked}},
title = {{Emergent Biosolutions — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/emergent-biosolutions}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001367644-26-000015 · February 27, 2026
{{cite web |title=Emergent Biosolutions — Key figures — 10-K (0001367644-26-000015) |url=https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.